Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) . Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available . A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.
|Number of pages||3|
|Publication status||Published - 12 Feb 2019|
- Factor Xa inhibitors
- Nitric oxide
FingerprintDive into the research topics of 'Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide'. Together they form a unique fingerprint.
- School of Applied Sciences - Clinical Principal Lecturer
- Medicines Optimisation Research and Enterprise Group